Novo Nordisk licensed global rights to Omeros’ zaltenibart, a MASP‑3 blocking antibody targeting complement‑mediated rare blood and kidney disorders, in a deal that could reach $2.1 billion plus royalties. Novo will lead pivotal development and plans Phase 3 testing in paroxysmal nocturnal hemoglobinuria (PNH) while evaluating other complement‑driven indications. Omeros said earlier data show tolerability and potential mechanistic advantages versus existing complement inhibitors; Novo characterized the acquisition as strategic expansion into complement therapeutics for rare diseases. The transaction highlights big‑pharma appetite for differentiated complement approaches.